Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Real Test for Gardasil: Money, not Morals

This article was originally published in RPM Report

Executive Summary

The real test for Gardasil isn't FDA approval or the Advisory Committee on Immunization Practices' recommendation for universal vaccination. In the long run, Gardasil's commercial success will be depend more on the future of the Vaccines for Children Act--and how long the government wants to continue to sign blank checks for childhood vaccinations.

You may also be interested in...



Gardasil Pushes Vaccine Prices--and Markets--to New Heights

The Gardasil launch is arguably the event with the greatest impact on the public perception of the new opportunities in vaccines, since it offers the promise of preventing future cervical cancers by vaccinating young adolescent girls. The commercialization of Gardasil has been front page news throughout the summer.

Mind Your Bs and Ds

There is a new variable to consider in drug development: which Medicare coverage system is more desirable: the Part B system for physician-administered drugs or Part D for the traditional retail market. But why choose one when you can play in both?

Medicare Part B vs. Part D

Drug companies are struggling with which reimbursement strategy to pursue. It

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT125529

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel